Literature DB >> 20214431

Proton radiation in the management of localized cancer.

Harald Paganetti1, Hanne Kooy.   

Abstract

Proton radiation therapy has been available for decades. However, until recently it was only applied to a small number of patients at approximately 20 centers worldwide. Increased clinical experience with protons, as well as extensive research in the physics, biology and clinical aspects of proton therapy, have recently led to a huge interest in proton therapy among radiation oncologists. In addition, the cost for facilities is expected to decrease. Many proton therapy facilities are currently being built and planned worldwide. It is expected that the number of patients treated with protons will increase substantially in the near future. This article summarizes the rationale for (proton) radiation therapy and addresses the promises and challenges of proton-beam therapy in the management of localized cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214431     DOI: 10.1586/erd.10.2

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  4 in total

Review 1.  Radiation-Induced Cardiovascular Toxicities.

Authors:  Shahed N Badiyan; Lindsay L Puckett; Gregory Vlacich; Walter Schiffer; Lauren N Pedersen; Joshua D Mitchell; Carmen Bergom
Journal:  Curr Treat Options Oncol       Date:  2022-09-10

Review 2.  Range uncertainties in proton therapy and the role of Monte Carlo simulations.

Authors:  Harald Paganetti
Journal:  Phys Med Biol       Date:  2012-05-09       Impact factor: 3.609

3.  TOPAS Simulation of the Mevion S250 compact proton therapy unit.

Authors:  Michael Prusator; Salahuddin Ahmad; Yong Chen
Journal:  J Appl Clin Med Phys       Date:  2017-04-26       Impact factor: 2.102

4.  Gold Nanoparticle Enhanced Proton Therapy: Monte Carlo Modeling of Reactive Species' Distributions Around a Gold Nanoparticle and the Effects of Nanoparticle Proximity and Clustering.

Authors:  Dylan Peukert; Ivan Kempson; Michael Douglass; Eva Bezak
Journal:  Int J Mol Sci       Date:  2019-09-01       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.